Literature DB >> 11319238

Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95.

Y Sun1, A Savanenin, P H Reddy, Y F Liu.   

Abstract

Increased glutamate-mediated excitotoxicity seems to play an important role in the pathogenesis of Huntington's disease (Tabrizi, S. J., Cleeter, M. W., Xuereb, J., Taaman, J. W., Cooper, J. M., and Schapira, A. H. (1999) Ann. Neurol. 45, 25-32). However, how polyglutamine expansion in huntingtin promotes glutamate-mediated excitotoxicity remains a mystery. In this study we provide evidence that (i) normal huntingtin is associated with N-methyl-d-aspartate (NMDA) and kainate receptors via postsynaptic density 95 (PSD-95), (ii) the SH3 domain of PSD-95 mediates its binding to huntingtin, and (iii) polyglutamine expansion interferes with the ability of huntingtin to interact with PSD-95. The expression of polyglutamine-expanded huntingtin causes sensitization of NMDA receptors and promotes neuronal apoptosis induced by glutamate. The addition of the NMDA receptor antagonist significantly attenuates neuronal toxicity induced by glutamate and polyglutamine-expanded huntingtin. The overexpression of normal huntingtin significantly inhibits neuronal toxicity mediated by NMDA or kainate receptors. Our results demonstrate that polyglutamine expansion impairs the ability of huntingtin to bind PSD-95 and inhibits glutamate-mediated excitotoxicity. These changes may be essential for the pathogenesis of Huntington's disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11319238     DOI: 10.1074/jbc.M103501200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  87 in total

Review 1.  Huntington's disease.

Authors:  S Davies; D B Ramsden
Journal:  Mol Pathol       Date:  2001-12

2.  Wild-type HTT modulates the enzymatic activity of the neuronal palmitoyl transferase HIP14.

Authors:  Kun Huang; Shaun S Sanders; Rujun Kang; Jeffrey B Carroll; Liza Sutton; Junmei Wan; Roshni Singaraja; Fiona B Young; Lili Liu; Alaa El-Husseini; Nicholas G Davis; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2011-06-02       Impact factor: 6.150

Review 3.  Huntingtin in health and disease.

Authors:  Anne B Young
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

4.  The Huntington's disease mutation impairs Huntingtin's role in the transport of NF-κB from the synapse to the nucleus.

Authors:  Edoardo Marcora; Mary B Kennedy
Journal:  Hum Mol Genet       Date:  2010-08-25       Impact factor: 6.150

5.  Effects of mutant huntingtin on mGluR5-mediated dual signaling pathways: implications for therapeutic interventions.

Authors:  Shan-Shan Huang; Jun He; Dong-Ming Zhao; Xiao-Yuan Xu; Hui-Ping Tan; He Li
Journal:  Cell Mol Neurobiol       Date:  2010-07-20       Impact factor: 5.046

6.  Exploring the genetic underpinnings of brain and behavioral disorders.

Authors:  Wei-Dong Yao; Chun-Fang Wu
Journal:  J Neurogenet       Date:  2014 Mar-Jun       Impact factor: 1.250

Review 7.  Glutamate and neurotrophic factors in neuronal plasticity and disease.

Authors:  Mark P Mattson
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

8.  NR2A and NR2B receptor gene variations modify age at onset in Huntington disease.

Authors:  Larissa Arning; Peter H Kraus; Sandra Valentin; Carsten Saft; Jürgen Andrich; Jörg T Epplen
Journal:  Neurogenetics       Date:  2004-11-17       Impact factor: 2.660

Review 9.  Striatal glutamatergic mechanisms and extrapyramidal movement disorders.

Authors:  Thomas N Chase; Francesco Bibbiani; Justin D Oh
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

10.  Dysregulation of mitochondrial calcium signaling and superoxide flashes cause mitochondrial genomic DNA damage in Huntington disease.

Authors:  Jiu-Qiang Wang; Qian Chen; Xianhua Wang; Qiao-Chu Wang; Yun Wang; He-Ping Cheng; Caixia Guo; Qinmiao Sun; Quan Chen; Tie-Shan Tang
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.